American Chemical Society 230th National Meeting. Neurological disorders.
Ognjenovic
Marica
M
Thomson Scientific, Middlesex House, London, UK. Marica.Ognjenovic@thomson.com
Perry
Letitia
L
D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D053148:Caspase 3; D061945:Caspase Inhibitors; D010450:Endopeptidases / Q000187:drug effects; D006801:Humans; D049268:Positron-Emission Tomography; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors*; D051672:Shal Potassium Channels / Q000187:drug effects; D013329:Structure-Activity Relationship; D051844:alpha-Synuclein / Q000037:antagonists & inhibitors
D061945:Caspase Inhibitors; D011480:Protease Inhibitors; D018094:Receptors, Metabotropic Glutamate; D051672:Shal Potassium Channels; D051844:alpha-Synuclein; C104077:metabotropic glutamate receptor type 1; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; C505407:CASP3 protein, human; D053148:Caspase 3; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human